About Recursion Pharmaceuticals
Recursion Pharmaceuticals is a publicly listed company based in New York (United States) founded in 2013. Novel therapeutics are discovered using an AI-enabled drug platform. Recursion Pharmaceuticals has raised $456.66 million across 21 funding rounds from investors including Nvidia, Intermountain Healthcare and Bayer. Recursion Pharmaceuticals has completed 4 acquisitions, including Cyclica, Exscientia and Valence Labs. Its website recursion.com draws about 85 thousand monthly visits. Recursion Pharmaceuticals offers products and services including BioHive Supercomputer, LOWE LLM Agent, and Recursion Platform. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its competitors include BridgeBio, Moderna and C4 Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Recursion Pharmaceuticals was founded in 2013 and is headquartered in New York, United States. Operations center on biotechnology, where an AI platform is applied to drug discovery and development. Biological and chemical datasets are analyzed alongside machine learning models and a supercomputer to identify targets and design molecules. Emphasis is given to conditions with unmet needs, including cancers and rare diseases. Strategic partnerships are pursued to broaden therapeutic applications.
- Annual Revenue$74.68 M (USD)26.92as on Dec 31, 2025
- Net Profit-$644.76 M (USD)-39.06as on Dec 31, 2025
- EBITDA-$564.43 M (USD)-27.55as on Dec 31, 2025
- Total Equity Funding$456.66M (USD)
in 21 rounds
- Latest Funding Round$6M (USD), Seed
Feb 2024
- InvestorsNvidia
& 34 more
- Investments & AcquisitionsCyclica
& 3 more
Products & Services of Recursion Pharmaceuticals
Recursion Pharmaceuticals offers a comprehensive portfolio of products and services, including BioHive Supercomputer, LOWE LLM Agent, and Recursion Platform.
Supercomputer for processing large-scale biological and chemical data.
AI agent for drug discovery processes and data analysis.
Integrated platform for AI-enabled gene and compound profiling.
Apps and channels of Recursion Pharmaceuticals
its YouTube channel Recursion has 28.9K subscribers and 30 videos.
Videos from Recursion Pharmaceuticals
The most watched videos on Recursion Pharmaceuticals's YouTube channel, Recursion (28.9K subscribers). Click a video to play it here.
More on Recursion.
Funding Insights of Recursion Pharmaceuticals
Recursion Pharmaceuticals has successfully raised a total of $456.66M across 21 strategic funding rounds. The most recent funding activity was a Seed round of $6 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $456.66M
- Total Rounds 21
- Last Round Seed — $6M
- First Round $130,000
(Jan 2014)
- Investors Count 35
Latest 10 of 21 funding rounds of Recursion Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2024 | $6M | Seed | – | – | |
| Jul 2023 | $50M | Post-IPO | – | – | |
| Oct 2022 | $150M | Post-IPO | – | – | |
| Sep 2022 | $2.72M | Seed | – | – | |
| Sep 2020 | $245.9M | Series D | – | Leaps by Bayer, Casdin Capital | |
| Jul 2019 | $121M | Series C | – | Baillie Gifford | |
| Jun 2018 | $20.5M | Debt – Conventional | – | – | |
| Oct 2017 | $60M | Series B | – | DCVC | |
| Feb 2017 | $4M | Debt – Convertible | – | Square 1 Bank | – |
| Nov 2016 | $2.15M | Series A | – | Felicis Ventures | – |
35 investors in total: 35 institutional.
Investors in Recursion Pharmaceuticals
Recursion Pharmaceuticals has secured backing from 35 investors, including institutional and venture fund investors. Prominent investors backing the company include Nvidia, Intermountain Healthcare and Bayer.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are directed toward multiple sectors by Kinnevik. | 1936 | kinnevik.com | Stockholm, Sweden | |
Venture capital firm investing in life sciences sector | leaps.bayer.com | Leverkusen, Germany | ||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Venture capital is provided to biomedical technology startups. | cataliocapital.com | New York, United States | ||
Venture capital funding is provided by Samsara BioCapital in California. | samsaracap.com | Palo Alto, United States | ||
Venture capital firm focused on multiple sectors | dcvc.com | Palo Alto, United States | ||
Early-stage technology companies are funded by this venture capital firm. | epicvc.com | Salt Lake City, United States | ||
Seed and early-stage technology companies are funded by Lux Capital. | luxcapital.com | Menlo Park, United States | ||
Venture capital firm investing in the healthcare sector | intermountainventures.com | Salt Lake City, United States | ||
Early-stage investments in tech sectors are managed by the firm. | twosigmaventures.com | New York, United States |
Investor details for Recursion Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Recursion Pharmaceuticals
152 people are tracked at Recursion Pharmaceuticals (71 in leadership, 9 in board & advisors, 72 in team).
| Name | Role | Group |
|---|---|---|
Kristen Rushton | VP, Project Management & Chief of Staff | Leadership |
Matt Kinn | VP, Business Development & Corporate Initiatives | Leadership |
Najat Khan | Chief R&D Officer & Chief Commercial Officer | Leadership |
Jody Barbeau | Director, Scientific Communications | Leadership |
Fraser Cunningham | Associate Director, Medicinal Chemistry (drug Design) | Leadership |
Tim Claridge | Associate Director, NMR Analytics | Leadership |
Ashley Adams | Executive Director | Leadership |
Andrew Overton | Vice President Finance | Leadership |
Carl Brooks | Executive Director Of Chemistry | Leadership |
Denise Donnelly | Executive Business Partner | Leadership |
Teresa Anderson-Myers | Director Of Engineering | Leadership |
Chris Gibson | Co-Founder & CEO | Leadership |
Charles Baker | Vice President Of Technology Development | Leadership |
Brandon Bennett | Director Global People Operatoins | Leadership |
Estelle Hamelin | Associate Director, Discovery Data Management | Leadership |
Safiye C. | Director Of Data Science | Leadership |
Andrew Wedlake | Associate Director, Data Science | Leadership |
Ian Goodfellow | Vice President - Antivirals | Leadership |
Ben Mabey | CTO | Leadership |
Chandana Haque | Executive Director of Biotech Incubator | Leadership |
132 more people are available in the full profile.
Complete people profiles for Recursion Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Recursion Pharmaceuticals
Recursion Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol RXRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Apr 2021
- Listed onNASDAQ: RXRX
- Listed entityRecursion Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS75629V1044
- Share price$3.83 (-4.36% on the day) · 2026-10-13
- Market capitalisation$2.06B
- EPS (diluted, trailing year)$-1.04
- Volume (last session)19,761,668
Financials of Recursion Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $74.7M | -$644.8M | -$564.4M |
| 2024 | $58.8M | -$463.7M | -$442.5M |
| 2023 | $44.6M | -$328.1M | -$317.6M |
| 2022 | $39.8M | -$239.5M | -$226.2M |
| 2021 | $10.2M | -$186.5M | -$173.7M |
Detailed financial statements for Recursion Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Recursion Pharmaceuticals
Recursion Pharmaceuticals has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Cyclica, Exscientia and Valence Labs.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
AI-driven drug discovery and precision medicine solutions are provided. | exscientia.com | Oxford, United Kingdom | 2012 | Oct 2024 | •••• | |
Research and productization engine within Recursion that focuses on advancing the frontier of AI in drug discovery | valencelabs.com | Montreal, Canada | 2017 | May 2023 | $47.5M | |
Online AI-interfacedpredictive analytics platform for drug discovery and testing | cyclicarx.com | Toronto, Canada | 2010 | May 2023 | $40M | |
Provider of living informatics platform for preclinical in vivo drug research | vium.com | San Mateo, United States | 2013 | Jul 2020 | •••• |
Complete acquisition details for Recursion Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Recursion Pharmaceuticals
8 dated milestones of Recursion Pharmaceuticals across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Recursion Pharmaceuticals is founded.
- Funding First funding round of $130K.
- Acquisition Acquires Vium.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Valence Labs.
- Acquisition Acquires Cyclica.
- Funding Latest funding round, Seed, of $6.0M.
- Acquisition Acquires Exscientia.
Competitors of Recursion Pharmaceuticals
Recursion Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Moderna and C4 Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of Recursion Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Recursion Pharmaceuticals
The website of Recursion Pharmaceuticals (recursion.com) receives about 85.2K visits a month.
- Monthly visits85.2K
▲ 16.1% vs previous month
Websites whose visitors overlap most with Recursion Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| lilly.com | 100% | 4.9M | #13,252 | View details | |
| clinicaltrials.gov | 100% | 3.3M | #13,034 | View details | |
| protouchstaffing.com | 94% | 8.9K | #2,366,444 | View details | |
firstwordpharma.com | firstwordpharma.com | 94% | #237,108 | – | |
| studypages.com | 94% | #841,099 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 26 similar websites and full traffic analytics for Recursion Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 26 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Recursion Pharmaceuticals (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Recursion Pharmaceuticals
Complete news archive for Recursion Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Recursion Pharmaceuticals
Recursion Pharmaceuticals was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Recursion Pharmaceuticals is headquartered in New York, United States. It is registered at New York, New York, United States.
Recursion Pharmaceuticals is a funded company, having raised a total of $456.66M across 21 funding rounds to date. The company's 1st funding round was a Series A of $2.15M, raised on Jan 2014.
Annual revenue of Recursion Pharmaceuticals is $74.68M as on Dec 31, 2025.
Recursion Pharmaceuticals was founded in 2013 and is headquartered in New York, United States. Operations center on biotechnology, where an AI platform is applied to drug discovery and development. Biological and chemical datasets are analyzed alongside machine learning models and a supercomputer to identify targets and design molecules. Emphasis is given to conditions with unmet needs, including cancers and rare diseases. Strategic partnerships are pursued to broaden therapeutic applications.
Recursion Pharmaceuticals's top competitors include Moderna, BridgeBio and C4 Therapeutics.
Recursion Pharmaceuticals offers BioHive Supercomputer, LOWE LLM Agent, and Recursion Platform.
Yes, Recursion Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol RXRX.
Recursion Pharmaceuticals has made 4 acquisitions, including Cyclica, Exscientia, and Valence Labs.
Recursion Pharmaceuticals has 35 investors. Key investors include Nvidia, Intermountain Healthcare, Bayer, NIH, and Square 1 Bank.